Pulse Biosciences (NASDAQ:PLSE) Raised to Strong-Buy at Freedom Capmkts

Posted by Geri Gentry on Sep 11th, 2026

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) was upgraded by equities researchers at Freedom Capmkts to a “strong-buy” rating in a research note issued on Wednesday, Zacks reports.

Several other brokerages have also recently weighed in on PLSE. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Mizuho set a $45.00 price target on Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group boosted their price target on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Read Our Latest Analysis on Pulse Biosciences

Pulse Biosciences Trading Up 2.8%

Shares of PLSE opened at $54.43 on Wednesday. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -46.13 and a beta of 1.63. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $58.90. The firm has a fifty day simple moving average of $39.87 and a 200 day simple moving average of $28.84.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. As a group, research analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Pulse Biosciences

In other news, COO Liane Teplitsky acquired 1,036 shares of the stock in a transaction dated Wednesday, August 26th. The shares were bought at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the purchase, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at approximately $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 4,095 shares of company stock valued at $199,931. Company insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds have recently bought and sold shares of PLSE. BlackRock Inc. bought a new stake in Pulse Biosciences in the 2nd quarter valued at $40,672,000. Bank of America Corp DE acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth about $40,115,000. California State Teachers Retirement System boosted its holdings in shares of Pulse Biosciences by 2,600.0% during the 2nd quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after buying an additional 546,850 shares during the period. Portolan Capital Management LLC bought a new stake in shares of Pulse Biosciences during the 3rd quarter worth about $1,809,000. Finally, Brooklyn Investment Group boosted its holdings in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after buying an additional 100,081 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.